<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>CatsWannaBeCats.Com | Chu Carstens | Activity</title>
	<link>https://www.catswannabecats.com/members/cannoncannon27/activity/</link>
	<atom:link href="https://www.catswannabecats.com/members/cannoncannon27/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Chu Carstens.</description>
	<lastBuildDate>Tue, 07 Jul 2026 09:45:31 -0400</lastBuildDate>
	<generator>https://buddypress.org/?v=7.2.0</generator>
	<language>en-CA</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">9cd2202a1dab360975d0f09acc7b23a2</guid>
				<title>Chu Carstens posted an update: y.



 In overactive bladder (OAB) research, different [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/11634/</link>
				<pubDate>Sun, 01 Jun 2025 07:10:30 -0400</pubDate>

									<content:encoded><![CDATA[<p>y.</p>
<p> In overactive bladder (OAB) research, different biomarkers have been proposed as diagnostic tools and may be used to create individual patient profiles. Assessing the diagnostic performance of biomarkers would better outline their utility. Therefore, our aim was to investigate the diagnostic value of four urinary biomarkers human brain&hellip;<span class="activity-read-more" id="activity-read-more-11634"><a href="https://www.catswannabecats.com/activity/p/11634/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ee54f08c3b9695373c5db6fa98fa6aa9</guid>
				<title>Chu Carstens posted an update: Gilead announced plans in July to pay $300 million for a [&#133;]</title>
				<link>https://www.catswannabecats.com/activity/p/5905/</link>
				<pubDate>Sat, 31 May 2025 15:27:52 -0400</pubDate>

									<content:encoded><![CDATA[<p>Gilead announced plans in July to pay $300 million for a 49.9% stake in Tizona Therapeutics, with the option to buy the rest of the company for $1.25 billion. Whether Gilead follows through with the acquisition will hinge on how well Tizona&#8217;s investigational HLA-G inhibitor, TTX-080, fares in early-stage clinical trials.Hemolacria is a rare&hellip;<span class="activity-read-more" id="activity-read-more-5905"><a href="https://www.catswannabecats.com/activity/p/5905/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">0ffb5bb54d1b08a464ddade52655f394</guid>
				<title>Chu Carstens became a registered member</title>
				<link>https://www.catswannabecats.com/activity/p/5794/</link>
				<pubDate>Sat, 31 May 2025 15:19:24 -0400</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>